Dear Johnson & Johnson Stock Fans, Mark Your Calendars for October 13 Johnson & Johnson will report its third-quarter results on Oct. 13. Barchart · Oct 11
Vacunados con J&J, reforzados con ARNm, y pensando en la tercera dosis Sí, todos estamos agotados por la pandemia de covid. Desconcertados por los constantes cambios en la ciencia y en las directrices. Preocupados por la sucesión de nuevas y temibles variantes, cada una con su propio nombre, como los huracanes. Tribune News Service · Mar 9, 2022
The Daily Biotech Pulse: Pfizer Begins Late-Stage Pediatric COVID Pill Study, Midatech And J&J Unit Expand R&D Collaboration, AbbVie-Alvotech Settle Humira Dispute Here's a roundup of top developments in the biotech space over the last 24 hours. Benzinga · Mar 9, 2022
Johnson and Johnson talcum powder cancer lawsuits expose history of human experimentation on Black prisoners Company tested ingredients on Black inmates for years near Philadelphia, documents show The Independent UK · Mar 7, 2022
To be 1 in a million: ‘Who thinks it’s going to be you?’ BEND, Ore. — Monica Melkonian wanted the Johnson & Johnson COVID-19 vaccine. It was only one shot and then she would be protected against the virus. So she was thrilled when the vaccination clinic at the Deschutes County Fair & Expo Center on April 7 had her first choice. Tribune News Service · Mar 4, 2022
Johnson & Johnson Allowed To Move Ahead With Bankruptcy Strategy On Talc Lawsuits: WSJ In a federal bankruptcy court in Trenton, New Jersey, Judge Michael Kaplan ruled in favor of Johnson & Johnson's (NYSE: JNJ) controversial bankruptcy filing meant to settle 38,000 claims alleging its talc-based products caused cancer. Benzinga · Feb 28, 2022
J&J, distributors finalize $26B landmark opioid settlement Drugmaker Johnson & Johnson and three major distributors have finalized a nationwide settlement over their role in the opioid addiction crisis The Independent UK · Feb 25, 2022
The Daily Biotech Pulse: J&J Unit Announces Research Collaboration With Remix, Regencell Touts COVID Data, Decision Day For Agios Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Amylyx's ALS Treatment Regulatory Application To Be Reviewed By FDA Panel In Late March Benzinga · Feb 17, 2022
Vaccinated people less likely to get long Covid than unvaccinated, new study shows Review finds those who have received two doses of Pfizer/BioNTech, AstraZeneca or Moderna vaccine, or one dose of single-shot J&J vaccine, half as likely to develop long Covid symptoms The Independent UK · Feb 15, 2022
J&J starts trial on bankruptcy case under attack by Congress The controversial Johnson & Johnson bankruptcy strategy that’s drawn the ire of Congress faces a fresh trial this week, with the consumer products giant arguing that settling billions of dollars of talc liabilities in a single case is better for cancer victims than fighting thousands of individual claims. Tribune News Service · Feb 14, 2022
Johnson & Johnson faces push to force global ban on talc baby powder sales Move to hold shareholder vote follows withdrawal of product in US and Canada and lawsuits alleging link to cancer cases The Guardian - UK · Feb 6, 2022
Johnson & Johnson recipients can get third COVID shot in San Francisco SAN FRANCISCO — San Francisco health officials are allowing people who originally got the Johnson & Johnson COVID-19 vaccine to get a second booster shot — which would give them access to the same number of doses currently available to recipients of Pfizer-BioNTech or Moderna. Los Angeles Times · Feb 2, 2022
The Daily Biotech Pulse: Galapagos Appoints J&J Exec As CEO, Aridis Gets Funding For Antiviral Treatment, Moderna Starts Omicron-Specific Booster Study Here's a roundup of top developments in the biotech space over the last 24 hours: Benzinga · Jan 27, 2022
The Daily Biotech Pulse: Pfizer-BioNTech Starts Omicron-Specific Vaccine Study, J&J Misses On Topline, Sierra Oncology Reports Positive Data Here's a roundup of top developments in the biotech space over the last 24 hours. Benzinga · Jan 25, 2022